Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods: This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m 2) consumed an energy‐reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O‐R, and they consumed the energy‐reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24‐h recall was performed, along with measurements of anthropometric and serum biochemical parameters. Results: A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of −6.82 kg (95% CI −8.37 to −5.26) was observed in the O‐R group compared with −3.50 kg (−5.05 to −1.95, P = 0.021) in the placebo group. In contrast, the −6.02 kg (−7.68 to −4.36) orlistat and −4.68 kg (−6.64 to −2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O‐R combination. Conclusions: The O‐R combination was the most effective weight loss treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anthropometric Standardization Reference Manual
Lohman, T. J., Roache, A. F., & Martorell, R. (1992) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199208000-00020 · Cited by 2,764
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000380842.14048.7e · Cited by 1,600
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320 · cited 3×
“The doses for each medication were based on the amount required to achieve weight loss and beneficial effects (3,14).”
BackgroundMethodResveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723 · cited 1×
“Resveratrol also acts against obesity-related diseases by improving mitochondrial function, improving insulin sensitivity and decreasing lipid accumulation (1,6,7).”
BackgroundEfficacy of Lifestyle Modification for Long‐Term Weight Control
Wadden, T. A., Butryn, M. L., & Byrne, K. J. (2004) · Obesity Research · doi:10.1038/oby.2004.282 · Cited by 511 · cited 1×
“Although lifestyle improvement is the cornerstone for the treatment of obesity, its long-term efficacy is unfortunately limited (36) Therefore, pharmacotherapy can be an important adjuvant to diet and TABLE 1 Patients who did not complete the study and the reasons for their premature termination”
BackgroundRivera, L., Morón, R., Zarzuelo, A., & Galisteo, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.027 · Cited by 391 · cited 1×
“While the effects of resveratrol have been widely studied in animal models (8-13), few clinical studies concerning obesity have been performed, and the results are inconclusive.”
BackgroundWong, R. H. X., Howe, P. R. C., Buckley, J. D., Coates, A. M., Kunz, I., & Berry, N. M. (2011) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.03.003 · Cited by 277 · cited 1×
“The differing results could be due to the variable doses selected in the assays and to the different clinical backgrounds of the study subjects (14-17).”
BackgroundResveratrol and obesity: can resveratrol relieve metabolic disturbances?
de Ligt, M., Timmers, S., & Schrauwen, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.012 · Cited by 135 · cited 1×
“Although debate exists regarding the direct molecular target of resveratrol, the consensus is that its metabolic action converges on pathways involving adenosine monophosphate-activated kinase, Sirt1 (sirtuin 1) (through the inhibition of phosphodiesterases leading to its activation), and peroxisome proliferator-activ…”
BackgroundMetabolic effects of resveratrol: Addressing the controversies
Bitterman, J. L., & Chung, J. H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1808-8 · Cited by 109 · cited 1×
“Resveratrol also acts against obesity-related diseases by improving mitochondrial function, improving insulin sensitivity and decreasing lipid accumulation (1,6,7).”
BackgroundDose response biology of resveratrol in obesity
Scapagnini, G., Davinelli, S., Kaneko, T., Koverech, G., Koverech, A., Calabrese, E. J., & Calabrese, V. (2014) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-014-0257-3 · Cited by 31 · cited 1×
“It has been observed that resveratrol presents a dose–response hormesis in the biological models in which it has been tested, affecting several outcomes with medical and therapeutic significance (18).”
Background
Cited by
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Anti-Obesity Effects of Polyphenol Intake: Current Status and Future Possibilities
Boccellino, M., & D’Angelo, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165642 · Cited by 262
Resveratrol, Metabolic Syndrome, and Gut Microbiota
Chaplin, A., Carpéné, C., & Mercader, J. (2018) · Nutrients · doi:10.3390/nu10111651 · Cited by 242
“with other molecules, such as the intestinal lipase inhibitor orlistat [32] or epigallocatechin-3-gallate (EGCC) [49], did not show significant changes in fat mass.”
BackgroundBatista-Jorge, G. C., Barcala-Jorge, A. S., Silveira, M. F., Lelis, D. F., Andrade, J. M. O., de Paula, A. M. B., Guimarães, A. L. S., & Santos, S. H. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117962 · Cited by 55
Resveratrol Inhibits Human Visceral Preadipocyte Proliferation and Differentiation in vitro
Sun, W., Yu, S., Han, H., Yuan, Q., Chen, J., & Xu, G. (2019) · Lipids · doi:10.1002/lipd.12196 · Cited by 11
Metadata
- Authors
- Arzola‐Paniagua, M. A., García‐Salgado López, E. R., Calvo‐Vargas, C. G., & Guevara‐Cruz, M.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2016-05-25
- Volume
- 24
- Issue
- 7
- Pages
- 1454-1463
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2401467434
- Cited by
- 64
- References
- 10
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial. https://app.cochat.ai/papers/10.1002/oby.21523
- The paper
- Arzola‐Paniagua, M. A., García‐Salgado López, E. R., Calvo‐Vargas, C. G., & Guevara‐Cruz, M. (2016). Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial. Obesity. https://doi.org/10.1002/oby.21523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.